https://eradigm.com/ 2025-12-05T11:45:14+00:00 https://eradigm.com/our-team/ 2026-03-16T13:32:28+00:00 https://eradigm.com/data-privacy-notice/ 2025-02-28T15:43:22+00:00 https://eradigm.com/case-studies/ 2024-08-19T20:54:08+00:00 https://eradigm.com/our-services/ 2025-04-01T10:17:29+00:00 https://eradigm.com/our-mission/ 2025-04-01T10:16:21+00:00 https://eradigm.com/eradigm-team/ 2022-10-26T14:29:34+00:00 https://eradigm.com/blog/news/ 2022-10-13T16:20:31+00:00 https://eradigm.com/blog/articles/ 2022-10-13T16:20:32+00:00 https://eradigm.com/blog/white-papers/ 2024-08-19T20:57:04+00:00 https://eradigm.com/vacancies/what-does-a-consultant-do/ 2024-07-29T15:53:38+00:00 https://eradigm.com/vacancies/our-values/ 2023-04-15T13:39:52+00:00 https://eradigm.com/vacancies/who-we-are/ 2024-08-09T13:38:41+00:00 https://eradigm.com/vacancies/why-join-eradigm/ 2024-07-29T11:41:19+00:00 https://eradigm.com/vacancies/life-science-consulting-jobs/ 2025-04-01T10:29:45+00:00 https://eradigm.com/eradigm-privacy-policy-2022/ 2022-07-05T09:29:46+00:00 https://eradigm.com/immersive-experiences-that-deliver-transformational-value/ 2025-04-04T07:07:39+00:00 https://eradigm.com/experts-circles/ 2024-08-07T08:53:36+00:00 https://eradigm.com/diamond-insights-tv/series-2/ 2021-09-20T15:26:31+00:00 https://eradigm.com/ethos-and-benefits/ 2025-04-01T10:13:53+00:00 https://eradigm.com/privacy-policy/ 2021-08-06T12:27:04+00:00 https://eradigm.com/training-september/ 2021-08-03T12:11:24+00:00 https://eradigm.com/our-team/training/ 2023-05-11T10:54:06+00:00 https://eradigm.com/vacancies/ 2026-02-12T12:15:05+00:00 https://eradigm.com/our-philosophy/ 2021-07-30T10:57:33+00:00 https://eradigm.com/service-portfolio/ 2021-08-04T15:40:28+00:00 https://eradigm.com/vision/ 2022-06-13T09:36:10+00:00 https://eradigm.com/blog/ 2024-08-19T10:43:27+00:00 https://eradigm.com/contact-us/ 2025-04-01T08:57:01+00:00 https://eradigm.com/competitor-early-rd-processes/ 2024-08-21T18:47:03+00:00 https://eradigm.com/haematology-life-cycle-management/ 2024-08-19T15:23:24+00:00 https://eradigm.com/navigating-change-management-during-rd-prioritization-exercises/ 2024-08-19T15:20:58+00:00 https://eradigm.com/global-car-t-threat-monitoring/ 2024-08-19T15:18:10+00:00 https://eradigm.com/rare-disease-portfolio-launch-workshop/ 2024-08-19T15:18:56+00:00 https://eradigm.com/oncology-diagnostics-conference-coverage/ 2024-08-19T15:11:05+00:00 https://eradigm.com/infectious-disease-franchise-monitoring/ 2024-08-19T15:06:43+00:00 https://eradigm.com/echo-ecg-landscaping-assessment/ 2024-08-19T10:47:42+00:00 https://eradigm.com/preparing-healthcare-systems-for-broader-cgt-access/ 2024-07-30T15:48:58+00:00 https://eradigm.com/collaborating-for-better-outcomes/ 2024-07-30T15:56:46+00:00 https://eradigm.com/the-ripple-effects-of-healthcare-reforms-in-germany/ 2024-07-30T16:00:34+00:00 https://eradigm.com/the-evolving-role-of-provider-payer-and-patients-in-biosimilar-adoption/ 2024-07-30T16:06:22+00:00 https://eradigm.com/pharmaceutical-launch-strategies-in-europes-cost-saving-environment/ 2024-07-30T16:08:48+00:00 https://eradigm.com/what-are-the-pricing-and-repricing-mechanisms-in-japans-pr-system-that-pharma-must-understand-when-considering-a-launch-in-japan/ 2024-07-30T16:17:28+00:00 https://eradigm.com/preparing-for-successful-market-access-and-hta-assessments-in-europe/ 2024-07-30T16:34:48+00:00 https://eradigm.com/the-role-of-artificial-intelligence-in-revolutionising-drug-discovery/ 2024-08-19T12:30:52+00:00 https://eradigm.com/fdas-newest-contribution-to-the-real-world-evidence-revolution-innovative-frameworks-to-streamline-regulatory-submissions/ 2024-08-19T12:31:23+00:00 https://eradigm.com/the-future-of-patient-care-amidst-a-growing-digital-health-landscape/ 2024-08-19T12:31:56+00:00 https://eradigm.com/the-ripple-effects-of-healthcare-reforms-in-germany-a-reduced-free-pricing-period/ 2024-07-30T16:52:00+00:00 https://eradigm.com/the-evolution-of-early-access-programmes-eaps-design-for-gene-therapies-and-single-administration-treatments/ 2024-08-19T12:32:24+00:00 https://eradigm.com/pharmaceutical-corporate-sponsored-digital-incubators-is-this-an-answer-to-the-perennial-question-of-how-to-digitize-pharmaceutical-companies/ 2024-08-19T12:32:44+00:00 https://eradigm.com/white-paper/collaborating-for-better-outcomes/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/the-ripple-effects-of-healthcare-reforms-in-germany/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/the-evolving-role-of-provider-payer-and-patients-in-biosimilar-adoption/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/pharmaceutical-launch-strategies-in-europes-cost-saving-environment/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/what-are-the-pricing-and-repricing-mechanisms-in-japans-pr-system-that-pharma-must-understand-when-considering-a-launch-in-japan/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/preparing-for-successful-market-access-and-hta-assessments-in-europe/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/the-role-of-artificial-intelligence-in-revolutionising-drug-discovery/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/fdas-newest-contribution-to-the-real-world-evidence-revolution-innovative-frameworks-to-streamline-regulatory-submissions/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/the-future-of-patient-care-amidst-a-growing-digital-health-landscape/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/the-ripple-effects-of-healthcare-reforms-in-germany-a-reduced-free-pricing-period/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/the-evolution-of-early-access-programmes-eaps-design-for-gene-therapies-and-single-administration-treatments/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/pharmaceutical-corporate-sponsored-digital-incubators-is-this-an-answer-to-the-perennial-question-of-how-to-digitize-pharmaceutical-companies/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white-paper/preparing-healthcare-systems-for-broader-cgt-access/ 2024-07-30T14:30:19+00:00 https://eradigm.com/white_paper_reports/preparing-healthcare-systems-for-broader-cgt-access/ 2024-07-30T13:46:29+00:00 https://eradigm.com/team/sofia-syntaka/ 2024-10-21T13:42:02+00:00 https://eradigm.com/team/nephelie-vaporidou/ 2024-04-30T12:21:32+00:00 https://eradigm.com/team/natalia-zaczek/ 2023-10-04T08:09:58+00:00 https://eradigm.com/team/estela-ioannidou/ 2023-09-28T16:04:03+00:00 https://eradigm.com/team/eleanor-hollis/ 2023-09-28T15:03:31+00:00 https://eradigm.com/team/amy-murray/ 2023-09-28T14:59:43+00:00 https://eradigm.com/team/jessica-timms/ 2023-09-28T14:58:49+00:00 https://eradigm.com/team/sara-ahmad/ 2023-10-04T08:06:23+00:00 https://eradigm.com/team/madina-khusnullina/ 2023-09-28T15:11:39+00:00 https://eradigm.com/team/tiya-ravindran/ 2023-09-28T15:04:36+00:00 https://eradigm.com/team/zoe-ajayi/ 2023-09-28T16:00:03+00:00 https://eradigm.com/service/market-access/ 2024-03-05T11:52:42+00:00 https://eradigm.com/case-study/cell-gene-therapy-in-japan/ 2023-04-17T12:23:00+00:00 https://eradigm.com/case-study/competitor-launch-scenarios-across-eu-markets/ 2023-04-17T12:22:11+00:00 https://eradigm.com/case-study/country-prioritization-launch-sequencing/ 2023-04-17T12:21:17+00:00 https://eradigm.com/case-study/echo-and-ecg-landscape-assessment/ 2023-04-17T12:24:51+00:00 https://eradigm.com/case-study/factors-xia-competitor-messaging/ 2023-04-17T12:24:45+00:00 https://eradigm.com/case-study/ascvd-scientific-platform/ 2023-04-17T12:24:38+00:00 https://eradigm.com/case-study/ascvd-co-positioning-strategies/ 2023-04-17T12:24:25+00:00 https://eradigm.com/case-study/hiv-scenario-planning/ 2023-04-17T12:23:59+00:00 https://eradigm.com/case-study/diagnostics-pricing/ 2023-04-17T12:24:12+00:00 https://eradigm.com/case-study/lcm-opportunity-assessment/ 2023-04-16T18:40:59+00:00 https://eradigm.com/case-study/a1-ascvd-opportunity-mapping/ 2023-04-16T19:57:28+00:00 https://eradigm.com/workshops-that-actually-work-essential-principles-for-delivering-strategy-workshops-that-bond-engage-and-motivate-biopharma-teams/ 2024-08-19T12:33:06+00:00 https://eradigm.com/royalties-in-pharma-a-closer-look-at-the-company-which-owns-a-stake-in-a-quarter-of-all-blockbuster-drugs-and-the-growing-significance-of-the-model-they-created/ 2023-03-29T09:01:15+00:00 https://eradigm.com/continental-drift-why-pharma-companies-are-pulling-away-from-innovation-unfriendly-europe-and-how-biopharma-leaders-can-adapt/ 2023-03-29T14:29:52+00:00 https://eradigm.com/uncertain-fate-the-death-of-allogeneic-cell-therapy/ 2023-03-29T09:02:30+00:00 https://eradigm.com/team/natalie-poole/ 2023-11-23T11:36:03+00:00 https://eradigm.com/team/isaac-bryan/ 2024-04-30T12:19:14+00:00 https://eradigm.com/ai-powered-drug-discovery-buzzword-or-the-future/ 2024-08-19T12:34:06+00:00 https://eradigm.com/is-diga-the-way-forward-what-does-the-optimal-reimbursement-model-look-like/ 2024-08-19T12:34:24+00:00 https://eradigm.com/womens-health-is-greater-than-femtech-and-the-opportunity-is-huge/ 2024-08-19T12:35:00+00:00 https://eradigm.com/gene-therapies-can-the-industry-keep-up-its-momentum-or-will-it-burn-out/ 2024-08-19T12:35:20+00:00 https://eradigm.com/the-cutting-edge-of-biotech-the-continuous-drive-to-achieve-next-gen-greatness/ 2024-08-19T12:35:37+00:00 https://eradigm.com/access-for-one-access-for-all-if-no-longer-rare-how-will-biotech-ensure-sustainable-access-to-cgts-to-the-masses/ 2024-08-19T12:35:52+00:00 https://eradigm.com/throw-it-against-the-wall-and-see-what-sticks-players-testing-their-new-molecular-entities-in-numerous-immuno-oncology-or-autoimmune-settings-concurrently/ 2024-08-19T12:36:07+00:00 https://eradigm.com/assembling-all-the-bits-and-pieces-tackling-capacity-constraints-for-the-successful-rollout-for-neurological-therapies/ 2024-08-19T12:36:24+00:00 https://eradigm.com/venturing-into-the-unknown-how-pharma-is-embracing-neuroscience-rd-after-decades-of-failure/ 2024-08-19T12:36:38+00:00 https://eradigm.com/team/kamaal-lynch-samms/ 2023-11-23T11:37:33+00:00 https://eradigm.com/service/how-we-work/ 2022-07-07T14:50:34+00:00 https://eradigm.com/to-deliver-cell-and-gene-therapies-pharma-needs-to-spend-more-time-with-patients/ 2024-08-19T12:37:00+00:00 https://eradigm.com/oral-therapies-what-role-should-patient-support-programs-psps-play/ 2024-08-19T12:37:22+00:00 https://eradigm.com/customer-experience-in-healthcare-should-pharma-take-a-page-from-the-tech-industry/ 2024-08-19T14:30:14+00:00 https://eradigm.com/diversifying-clinical-trials-for-regulatory-success-one-size-does-not-fit-all/ 2024-08-19T14:32:04+00:00 https://eradigm.com/patient-centricity-in-drug-development-getting-it-right-the-first-time/ 2024-08-19T14:32:41+00:00 https://eradigm.com/talking-the-talk-pharmas-role-in-addressing-social-determinants-of-health/ 2024-08-19T14:34:08+00:00 https://eradigm.com/team/kalayvani-soondrum/ 2024-04-30T12:22:25+00:00 https://eradigm.com/team/paula-wegbrans-giro/ 2023-05-05T11:20:15+00:00 https://eradigm.com/facing-reality-the-power-behind-real-world-evidence-rwe-and-how-to-keep-up/ 2024-08-19T14:34:42+00:00 https://eradigm.com/fdas-project-optimus-a-revolution-of-the-oncology-clinical-development-paradigm-through-a-reform-of-drug-dose-optimization/ 2024-08-19T14:35:03+00:00 https://eradigm.com/team/nadeen-solaiman/ 2024-04-29T10:34:23+00:00 https://eradigm.com/team/oliver-odell/ 2024-04-29T10:31:25+00:00 https://eradigm.com/team/shreya-murali/ 2023-11-23T11:40:52+00:00 https://eradigm.com/liquid-biopsies-bio-marking-an-era-of-precision-medicine/ 2024-08-19T14:35:18+00:00 https://eradigm.com/team/nick-waring/ 2023-11-23T11:38:21+00:00 https://eradigm.com/team/jeanne-claire-vincent-2/ 2023-05-04T12:49:50+00:00 https://eradigm.com/team/barney-poznansky/ 2023-11-23T11:40:05+00:00 https://eradigm.com/hail-the-slow-burner-nows-the-time-to-fire-up-your-cross-portfolio-competitive-intelligence-function/ 2024-08-19T14:35:38+00:00 https://eradigm.com/jumping-on-the-bandwagon-western-pharma-seeks-to-capture-the-innovation-erupting-from-china-through-hands-on-partnering-initiatives/ 2024-08-19T14:45:04+00:00 https://eradigm.com/a-sleeping-cgt-giant-awakening-will-china-partner-or-pioneer/ 2024-08-19T14:45:22+00:00 https://eradigm.com/case-study/competitor-positioning-workshop/ 2023-03-23T09:04:00+00:00 https://eradigm.com/case-study/medical-affairs-launch-strategy/ 2021-09-22T09:21:09+00:00 https://eradigm.com/case-study/landscape-analysis-of-the-chinese-car-t-market/ 2021-09-21T11:53:16+00:00 https://eradigm.com/case-study/benchmarking-competitor-digital-platforms/ 2021-09-21T15:22:46+00:00 https://eradigm.com/case-study/benchmarking-competitor-patient-services/ 2021-09-21T15:21:21+00:00 https://eradigm.com/case-study/cell-therapy-competitive-landscap-monitoring/ 2021-09-21T15:19:51+00:00 https://eradigm.com/case-study/competitor-post-script-services/ 2021-09-22T09:38:45+00:00 https://eradigm.com/case-study/market-specific-pre-loe-pricing/ 2021-09-21T11:15:57+00:00 https://eradigm.com/case-study/portfolio-market-access-strategy/ 2021-09-21T11:55:45+00:00 https://eradigm.com/case-study/monitoring-key-competitors/ 2021-09-21T11:21:07+00:00 https://eradigm.com/expert-circles/china/ 2023-04-20T13:13:01+00:00 https://eradigm.com/expert-circles/oncology-haematology/ 2023-04-20T13:09:48+00:00 https://eradigm.com/expert-circles/digital-innovation/ 2023-04-20T13:12:34+00:00 https://eradigm.com/expert-circles/neuroscience-immunology/ 2023-04-20T13:10:03+00:00 https://eradigm.com/expert-circles/beyond-the-pill/ 2023-04-14T20:05:47+00:00 https://eradigm.com/expert-circles/rare-diseases-cell-gene-therapy/ 2023-04-20T13:10:33+00:00 https://eradigm.com/case-study/rare-disease-portfolio-launch-competitive-workshop/ 2023-03-23T09:11:44+00:00 https://eradigm.com/case-study/portfolio-corporate-strategy-workshop/ 2023-03-23T09:10:32+00:00 https://eradigm.com/insights/prescribing-digital-could-digital-tools-be-the-panacea-for-market-access/ 2021-09-20T15:19:43+00:00 https://eradigm.com/insights/future-proofing-pharma-what-determines-success-for-pharma-when-it-comes-to-digital-transformation/ 2021-09-20T15:19:17+00:00 https://eradigm.com/insights/demystifying-digital-health-how-are-digital-advances-impacting-the-patient-journey/ 2021-09-20T15:18:51+00:00 https://eradigm.com/team/marcus-deans-mba/ 2022-11-01T16:00:24+00:00 https://eradigm.com/team/patrick-romano-phd/ 2024-05-13T08:15:41+00:00 https://eradigm.com/team/brynna-hoggard/ 2023-11-23T11:40:28+00:00 https://eradigm.com/digital-health-patient-data-elevating-the-ceiling-across-pharmas-entire-value-chain/ 2024-08-19T14:45:51+00:00 https://eradigm.com/could-digital-patient-services-influence-future-payer-negotiations/ 2024-08-19T14:46:15+00:00 https://eradigm.com/how-is-pharma-using-digital-clinical-trials-to-outpace-its-competitors/ 2024-08-19T14:46:41+00:00 https://eradigm.com/case-study/6-china-innovation-strategy/ 2023-03-23T09:01:04+00:00 https://eradigm.com/case-study/5-allogeneic-cell-therapy-corporate-strategy/ 2022-06-13T15:23:07+00:00 https://eradigm.com/case-study/4-immunology-patient-services-ci/ 2022-06-13T16:14:12+00:00 https://eradigm.com/case-study/3-accelerating-immunotherapy-development/ 2022-06-13T16:13:05+00:00 https://eradigm.com/case-study/2-atrial-fibrillation-screening/ 2022-06-13T15:32:36+00:00 https://eradigm.com/case-study/1-global-car-t-market-access-strategy/ 2023-03-23T09:14:30+00:00 https://eradigm.com/insights/the-golden-ratio-measuring-the-true-value-of-car-t/ 2022-06-13T10:16:20+00:00 https://eradigm.com/insights/the-ripple-effect-the-positive-impact-of-expanding-access-to-car-t/ 2021-08-10T14:28:03+00:00 https://eradigm.com/insights/a-brighter-future-how-advances-in-manufacture-could-open-the-market-for-cart-t/ 2022-06-13T10:28:35+00:00 https://eradigm.com/faculty/greg-searle/ 2021-06-29T09:08:58+00:00 https://eradigm.com/faculty/ollie-hirst/ 2021-06-29T09:05:57+00:00 https://eradigm.com/faculty/chrissie-wellington-obe/ 2022-06-13T10:40:00+00:00 https://eradigm.com/faculty/dr-rohin-iyer/ 2022-06-13T10:45:14+00:00 https://eradigm.com/faculty/dr-joseph-mikhael/ 2021-07-28T15:36:42+00:00 https://eradigm.com/faculty/dr-alvaro-urbano-ispizua/ 2022-06-13T10:35:55+00:00 https://eradigm.com/faculty/alexis-puhan/ 2021-07-28T15:35:45+00:00 https://eradigm.com/faculty/jennifer-quinton/ 2022-06-13T10:22:26+00:00 https://eradigm.com/faculty/kay-abesamis/ 2021-07-28T15:02:54+00:00 https://eradigm.com/faculty/tamara-oei/ 2021-07-28T14:57:36+00:00 https://eradigm.com/faculty/louise-crowley/ 2021-07-28T14:59:56+00:00 https://eradigm.com/faculty/martyn-smith/ 2021-07-28T14:54:14+00:00 https://eradigm.com/faculty/chris-lew/ 2021-07-28T14:58:53+00:00 https://eradigm.com/faculty/luca-durbino/ 2021-06-29T08:37:21+00:00 https://eradigm.com/service/intelligence-insights/ 2023-04-20T13:18:32+00:00 https://eradigm.com/service/commercial-strategy/ 2023-06-01T08:59:46+00:00 https://eradigm.com/case-study/therapy-area-1/ 2023-04-16T19:43:48+00:00 https://eradigm.com/the-future-of-work-in-the-life-sciences-how-eradigm-are-leading-the-charge-post-covid/ 2024-08-19T14:47:02+00:00 https://eradigm.com/accelerating-into-hyperspace-from-automation-to-in-process-sampling-how-novel-approaches-in-car-t-manufacture-could-deliver-greater-speed/ 2024-08-19T14:47:22+00:00 https://eradigm.com/venturing-out-how-advances-in-remote-monitoring-solutions-and-tools-may-be-the-key-to-widening-car-t-treatment-into-the-community/ 2024-08-19T14:47:42+00:00 https://eradigm.com/from-last-line-to-frontline-clinical-trials-and-a-growing-chorus-of-expert-opinion-suggest-car-ts-true-value-lies-in-an-early-line-treatment/ 2024-08-19T14:47:57+00:00 https://eradigm.com/turning-pharma-inside-out-its-time-big-pharma-applied-the-same-curiosity-to-its-purpose-as-it-does-to-the-science/ 2024-08-19T14:48:30+00:00 https://eradigm.com/digital-therapeutics-big-pharma-faces-an-identity-crisis/ 2024-08-19T14:48:55+00:00 https://eradigm.com/value-based-healthcare-is-here-to-stay-pharma-needs-to-embrace-it-or-risk-getting-cut-out-of-the-conversation/ 2024-08-19T14:49:09+00:00 https://eradigm.com/the-hare-and-the-tortoise-race-to-market-pharma-needs-to-re-think-responsible-trial-innovation-for-improved-patient-access-rather-than-just-speed/ 2024-08-19T14:49:26+00:00 https://eradigm.com/putting-patients-first-or-else-pharma-needs-to-shift-into-gear-and-design-patient-support-programs-that-benefit-the-entire-healthcare-ecosystem-vs-their-bottom-line/ 2024-08-19T14:49:40+00:00 https://eradigm.com/lifesavers-to-legacy-covid-19-has-put-partnership-and-innovation-back-at-the-heart-of-pharma/ 2024-08-19T14:49:53+00:00 https://eradigm.com/the-winds-of-change-are-blowing-from-the-east-why-and-how-western-pharma-should-get-ready-to-sow-the-seeds-now/ 2024-08-19T14:50:22+00:00 https://eradigm.com/how-to-shapeshift-through-partnering-rewriting-fate-through-visionary-leaps-and-agile-collaborations/ 2024-08-19T14:50:40+00:00 https://eradigm.com/how-the-covid-crisis-gave-pharma-its-mojo-back-and-how-to-keep-it/ 2024-08-19T14:50:55+00:00 https://eradigm.com/to-win-in-car-t-you-need-much-more-than-data-the-customer-is-king/ 2024-08-19T14:51:16+00:00 https://eradigm.com/it-is-time-for-pharma-to-pick-a-side-choose-public-health-or-get-left-out-in-the-cold/ 2024-08-19T14:51:31+00:00 https://eradigm.com/from-binge-eating-to-lifestyle-change-pharma-competitive-strategy/ 2024-08-19T14:52:40+00:00 https://eradigm.com/case-study/corporate-strategy-4/ 2023-03-23T13:39:17+00:00 https://eradigm.com/case-study/corporate-strategy-2/ 2023-03-23T13:37:46+00:00 https://eradigm.com/case-study/therapy-area-5/ 2023-03-23T13:36:28+00:00 https://eradigm.com/case-study/therapy-area-6/ 2023-03-23T13:34:11+00:00 https://eradigm.com/case-study/corporate-strategy-3/ 2023-03-23T13:38:25+00:00 https://eradigm.com/case-study/therapy-area-4/ 2023-03-23T13:32:34+00:00 https://eradigm.com/case-study/therapy-area-3/ 2023-03-23T13:31:52+00:00 https://eradigm.com/case-study/therapy-area-2/ 2023-03-23T13:30:58+00:00 https://eradigm.com/case-study/product-strategy-6/ 2021-08-05T13:32:44+00:00 https://eradigm.com/case-study/product-strategy-5/ 2021-08-05T13:32:04+00:00 https://eradigm.com/case-study/product-strategy-4/ 2021-08-05T13:31:21+00:00 https://eradigm.com/case-study/product-strategy-3/ 2021-08-05T13:30:22+00:00 https://eradigm.com/case-study/product-strategy-2/ 2021-08-05T13:14:51+00:00 https://eradigm.com/case-study/product-strategy-1/ 2021-08-05T13:14:08+00:00 https://eradigm.com/case-study/corporate-strategy-6/ 2023-03-23T13:02:18+00:00 https://eradigm.com/case-study/investment-strategy-2/ 2023-03-24T10:00:51+00:00 https://eradigm.com/case-study/corporate-strategy-1/ 2023-03-23T13:40:53+00:00 https://eradigm.com/case-study/pricing-reimbursement-market-access-2/ 2023-03-23T09:17:03+00:00 https://eradigm.com/case-study/investment-strategy-1/ 2023-03-24T09:59:13+00:00 https://eradigm.com/case-study/commercial-excellence-2/ 2023-03-24T09:30:29+00:00 https://eradigm.com/case-study/commercial-excellence/ 2023-03-23T13:49:02+00:00 https://eradigm.com/case-study/pricing-reimbursement-market-access-1/ 2023-03-23T13:11:05+00:00 https://eradigm.com/case-study/established-products-and-franchise-strategy-2/ 2023-03-23T13:29:55+00:00 https://eradigm.com/case-study/established-products-and-franchise-strategy-1/ 2023-03-23T13:15:49+00:00 https://eradigm.com/case-study/new-product-strategy-3/ 2023-03-23T09:16:23+00:00 https://eradigm.com/case-study/portfolio-licensing-development-strategy-1/ 2021-08-05T12:54:22+00:00 https://eradigm.com/case-study/portfolio-licensing-development-strategy-2/ 2021-08-05T12:54:52+00:00 https://eradigm.com/case-study/new-product-strategy-1/ 2023-03-23T09:09:32+00:00 https://eradigm.com/case-study/cross-portfolio-strategy-2/ 2021-08-04T15:40:53+00:00 https://eradigm.com/case-study/new-product-strategy-2/ 2021-09-09T14:37:32+00:00 https://eradigm.com/case-study/cross-portfolio-strategy-1/ 2021-08-05T10:41:01+00:00 https://eradigm.com/case-study/corporate-strategy-5/ 2023-03-23T13:40:07+00:00